Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06736600 · ClinicalTrials.gov registry record · NA

Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial

A NA study of Peripheral Neuropathy Due to Chemotherapy, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT06736600 is a NA study of Peripheral Neuropathy Due to Chemotherapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants, below the 54-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06736600, a NA study of Peripheral Neuropathy Due to Chemotherapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

A behavioral trial aimed at helping patients identify what matters most to them and is part of a larger effort to pivot from disease-oriented care to whole-person care.

Interventions

  • BEHAVIORAL Goal Attainment Scaling (GAS)

Study Locations (1)

Texas

  • The University of Texas M. D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2025-04-18
Est. Completion 2027-08-31
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT06736600

The ClinicalTrials.gov registry entry for NCT06736600 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 54-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (17% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peripheral Neuropathy Due to Chemotherapy appearing as the primary indexed condition, and to 1 intervention - of which Goal Attainment Scaling (GAS) is the first listed.

NCT06736600 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06736600 about?

NCT06736600 is a clinical study titled "Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial". A behavioral trial aimed at helping patients identify what matters most to them and is part of a larger effort to pivot from disease-oriented care to whole-person care.

What is the current status of trial NCT06736600?

This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2025-04-18. Estimated completion is 2027-08-31.

What conditions does trial NCT06736600 study?

This clinical trial studies the following conditions: Peripheral Neuropathy Due to Chemotherapy.

What interventions are being tested in trial NCT06736600?

The interventions under investigation include: Goal Attainment Scaling (GAS) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06736600?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06736600 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Neuropathy Due to Chemotherapy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.